This antibody can be used for HLA typing.
| Inventor | Institute |
|---|---|
| Walter Bodmer | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 151078 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Immunology |
| Application: | FACS ; FACS |
| Target: | HLA-B7 |
| Reactivity: | Human |
| Clone: | BB7.1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | This antibody can be used for HLA typing. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Papain solubilised HLA-A2, B7 |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | Human Leukocyte Antigens are highly polymorphic proteins that are involved in the presentation of antigens to the T-cell receptor. There are two classes of HLA antigens, class I (HLA-A, HLA-B and HLA-C) and class II (HLA-D). |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | '-15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Reches et al. 2016. J Immunol. :. PMID: 27194785. HNRNPR Regulates the Expression of Classical and Nonclassical MHC Class I Proteins. Dellgren et al. 2015. PLoS One. 10(8):e0135385. PMID: 26258424. Cell surface expression level variation between two common Human Leukocyte Antigen alleles, HLA-A2 and HLA-B8, is dependent on the structure of the C terminal part of the alpha 2 and the alpha 3 domains. Rancan et al. 2015. PLoS Pathog. 11(6):e1004906. PMID: 26067064. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. Levering et al. 2000. Cytometry. 42(2):95-105. PMID: 10797446. External quality assessment of flow cytometric HLA-B27 typing. Parham et al. 1981. Hum Immunol. 3(4):277-99. PMID: 7035415. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Brodsky et al. 1979. Immunol Rev. 47:3-61. PMID: 95015. Monoclonal antibodies for analysis of the HLA system. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.